U2 snRNP associated SURP domain containingGenealiases: SR140 · fSAPa
Q-omics provides the consensus-scored U2SURP profile across patient tissues and cancer cell-line models. U2SURP expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, U2SURP is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, U2SURP protein abundance shows 32,134 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where U2SURP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for U2SURP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes U2SURP survival associations across molecular data types. U2SURP RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible U2SURP RNA expression–survival associations across cancer types. High U2SURP expression shows unfavorable associations in MESO, KICH, LIHC, ACC and PAAD, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for U2SURP RNA expression.
This table summarizes U2SURP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for U2SURP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. U2SURP shows higher tumor expression in HNSC, LIHC, BLCA, KIRC, STAD and LUSC. The HNSC box plot shows higher U2SURP RNA expression in tumor versus normal tissue (log2 FC = +1.353, t-test p < 0.001).
This table shows molecular features associated with U2SURP in patient tissues and cancer cell lines. In patient samples, U2SURP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, U2SURP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
